Juglanin

Juglanin, a occurring flavonoid that can be isolated from crude Polygonum aviculare, is a JNK acticator, with anti-inflammatory, anti-oxidant and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells^[1][2]. IC50 & Target::IC50: 26.35 μM (MCF-7 24 h), 20.07 μM (SKBR3 24 h), 29.13 μM (MDA-MB-231 24 h), 24.17 μM (BT474 24 h)^[1] IC50: 14.38 μM (MCF-7 48 h), 17.69 μM (SKBR3 48 h), 23.25 μM (MDA-MB-231 48 h), 19.85 μM (BT474 48 h)^[1] In Vitro:Juglanin (0-40 μM, 24-48 h) inhibits the proliferation of breast cancer cell in a dose- and time-dependent manner and presents less cytotoxic against the normal cells^[1].
Juglanin (0-10 μM, 24 h) induces the G2/M phase arrest and Caspase-dependent apoptosis in MCF-7/SKBR3 cells^[1].
Juglanin (10 μM, 24 h) promotes ROS generation and enhances JNK activation in MCF-7/SKBR3 cells^[1].
Juglanin (40-160 μM, 24 h) inhibits inflammation and attenuates neuroinflammation in Lipopolysaccharides (LPS, HY-D1056)-treated AST cells^[2].
Juglanin (40 μM, 24 h) inhibits Sting expression in TGF-β1-incubated MRC-5 cells^[3].
In Vivo:Juglanin (10-20 mg/kg, i.p., daily, 7 days) inhibits growth of human breast cancer xenograft in a tumor-transplanted mouse model^[1].
Juglanin (10-30 mg/kg, i.p., 5 times weekly) ameliorates neuroinflammation-related memory impairment and neurodegeneration through impeding TLR4/NF-κB in C57BL6 male mice^[2].
Juglanin (80 mg/kg, i.g., daily, 21 days) protects against bleomycin (BLM, HY-108345)-induced lung injury by inhibiting fibrosis in C57BL/6 male mice^[3].